- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Ozempic tops new Medicare price negotiation list | ||
| Fr | CDC wants faster testing for bird flu in hospitals | ||
| Fr | AI 'can spot cognitive decline linked to menopause' | ||
| Fr | Boehringer drug for brain fog in schizophrenia fails trial | ||
| Fr | Kardigan raises $300m for cardio work, and other financings | ||
| Fr | AZ's Calquence gets first-line OK in mantle cell lymphoma | ||
| Do | FDA bans red dye used in medicines over cancer risk | ||
| Do | Bioptimus raises $41m for its genAI model for biology | ||
| Do | Santhera preps UK Duchenne drug launch after NICE says yes | ||
| Do | J&J files intravesical bladder cancer drug TAR-200 in US | ||
| Do | Lilly nets a second FDA okay for Omvoh, in Crohn's disease | ||
| Mi | Keros pulls study of Winrevair rival after safety signal | ||
| Mi | Lilly trims sales forecast on weaker obesity/diabetes growth | ||
| Mi | FTC doubles down on PBM criticism in new report | ||
| Mi | Sling shoots at thyroid eye disease with its oral therapy | ||
| Mi | Obesity needs a new definition, says global commission | ||
| Di | AIs can be used for fracture detection, says NICE | ||
| Di | Grifols gets $21m award for Parkinson's biomarker hunt | ||
| Di | FDA sets August date for subcutaneous Leqembi decision | ||
| Di | Bayer gains ground in two-fronted Parkinson's offensive | ||
| 13.01. | Lilly nets Scorpion cancer drug in $2.5bn licensing deal | ||
| 13.01. | Regeneron, Illumina join $320m Truveta investment | ||
| 13.01. | J&J agrees $14.6bn takeover of CNS biotech Intra-Cellular | ||
| 13.01. | GSK confirms plan to buy cancer firm IDRx for $1bn | ||
| 13.01. | Nine-month-old obesity player Metsera files an IPO |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
